Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis

Annals of Allergy, Asthma & Immunology - Tập 95 - Trang 600-606 - 2005
Eli O. Meltzer1,2, Frank C. Hampel3, Paul H. Ratner4, David I. Bernstein5,6, Lawrence V. Larsen7, William E. Berger8,9, Albert F. Finn10, Bradley F. Marple11, Peter S. Roland11, G.M. Wall12, Michael J. Brubaker12, Carolyn Dimas12, Susan L. Potts12, Lewis H. Silver12, J. Rod Barnes12
1Allergy and Asthma Medical Group and Research Center, San Diego, California
2Division of Immunology and Allergy, Department of Pediatrics, University of California, San Diego, California.
3Central Texas Health Research, New Braunfels and San Antonio, Texas.
4Sylvana Research, San Antonio, Texas
5Bernstein Clinical Research Center, Cincinnati, Ohio.
6Division of Immunology, Department of Clinical Medicine, University of Cincinnati, Cincinnati, Ohio.
7Intermountain Clinical Research, Salt Lake City, Utah.
8Southern California Research, Mission Viejo, California
9Division of Allergy and Immunology, Department of Pediatrics, University of California, Irvine, California.
10Department of Family Medicine, Internal Medicine, Microbiology, and Immunology, Medical University of South Carolina, Charleston, South Carolina.
11Department of Otolaryngology–Head and Neck Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
12Alcon Research Ltd, Fort Worth, Texas.

Tài liệu tham khảo

Salzano, 1992, Allergic rhinoconjunctivitis: diagnostic and clinical assessment, Rhinology., 30, 265 Hollingsworth, 1996, Allergic rhinoconjunctivitis: current therapy, Hosp Pract (Off Ed)., 31, 61 Yanni, 1996, The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergy/antihistaminic agent, J Ocul Pharmacol Ther., 12, 256, 10.1089/jop.1996.12.389 Sharif, 1996, Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases, J Pharmacol Exp Ther., 278, 1252 Ohmori, 2002, Pharmacological, phar-macokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug, Jpn J Pharmacol., 88, 379, 10.1254/jjp.88.379 Miyake, 2001, Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs, Jpn J Pharmacol., 85, 453, 10.1254/jjp.85.453 Food and Drug Administration. Guidance for industry: allergic rhinitis: clinical development programs for drug products (draft guidelines). Available at: http://www.fda.gov/cder/guidance/2718dft.htm. Accessed July 7, 2005. Guyatt, 1992, Measuring health status: what are the necessary measurement properties?, J Clin Epidemiol., 45, 1341, 10.1016/0895-4356(92)90194-R Juniper, 1995, How to develop and validate a new quality of life instrument., 49 Juniper, 1991, Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis, Clin Exp Allergy., 21, 77, 10.1111/j.1365-2222.1991.tb00807.x Westfall, 1999, Concepts and basic methods for multiple comparisons and tests, 13 Tamura, 2003, Effects of orally administered olopatadine hydrochloride on the ocular allergic reaction in rats, Allergol Int., 52, 77, 10.1046/j.1440-1592.2003.00281.x Schoenwetter, 2004, Economic impact and quality-of-life burden of allergic rhinitis, Curr Med Res Opin., 20, 304, 10.1185/030079903125003053 2004